Youngjoo Kwon
이화여자대학교 식품생명공학전공 · 생화학·유전·분자생물학
Youngjoo Kwon 교수의 연구실은 암 생물학과 약리학의 핵심 메커니즘을 규명하고, 특히 치료 대상이 부족한 암 종양, 예를 들어 삼중음성유방암과 난소세포암의 분자적 기전을 탐구하고 있습니다. 주요 연구 방향은 암의 진행과 전이를 조절하는 전사인자, 혈관신생, 그리고 암세포의 약물 저항성 메커니즘을 타겟으로 한 신약 후보 물질 개발입니다. 또한, 단백질-핵산 상호작용을 모ulating하는 유기합성 분자 설계를 통해 표적 치료 전략을 개발하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Breast cancer accounts for 25% of all types of cancer in women, and triple negative breast cancer (TNBC) comprises around 15~20% of breast cancers. Conventional chemotherapy and radiation are the primary systemic therapeutic strategies; no other FDA-approved targeted therapies are yet available as for TNBC. TNBC is generally characterized by a poor prognosis and high rates of proliferation and metastases. Due to these aggressive features and lack of targeted therapies, numerous attempts have bee
Regulation of gene expression by transcription factors touches many aspects of eukaryotic biology, and its systematic, external control by organic molecules represents a challenge in chemistry. Here we report the design of a completely organic, nonpeptidic compound that mimics a transcription factor. The design takes advantage of the specific DNA-binding affinity of a hairpin polyamide molecule and the ability of wrenchnolol to bind to the Sur-2 subunit of human mediator complex. The hybrid comp
Human serum albumin (HSA) is the most abundant protein in the human body. HSA injections prepared by fractionating human blood have mainly covered the demand for albumin to treat hypoalbuminemia, the state of low concentration of albumin in blood. HSA in solution may exist in various forms such as monomers, oligomers, polymers, or as mixtures, and its conformational change and/or aggregation may occur easily. Considering these characteristics, there is a great chance of modification and polymer
